Celcuity’s gedatolisib cleared a major trial milestone in Phase 3 breast cancer testing by hitting its primary endpoint, lifting the company toward a regulatory filing for a second submission. The pan-PI3K/mTOR inhibitor is already under FDA review for a prior context, and the new positive result strengthens the clinical case for expanded label consideration. Celcuity’s update is notable for investors because Phase 3 success is often what determines whether an oncology asset can translate into sustainable market access; it also affects willingness of payers and guideline committees to adopt a therapy. With the mechanism targeting the PI3K/mTOR axis, responders and resistance patterns will likely be key to future positioning. The immediate next catalysts are the second submission details—review timing, whether confirmatory evidence aligns with existing submissions, and how safety tolerability is characterized relative to earlier datasets.